| Autor: |
Agrifoglio O; Department of Medicine II, Division of Gastroenterology and Endocrinology, Rostock University Medical Center, 18057 Rostock, Germany., Kasprick A; Lübeck Institute of Experimental Dermatology and Center for Research on Inflammation of the Skin, University of Lübeck, 23562 Lübeck, Germany., Gross N; Lübeck Institute of Experimental Dermatology and Center for Research on Inflammation of the Skin, University of Lübeck, 23562 Lübeck, Germany., Wahlig M; Department of Medicine II, Division of Gastroenterology and Endocrinology, Rostock University Medical Center, 18057 Rostock, Germany., Kauffold E; Department of Medicine II, Division of Gastroenterology and Endocrinology, Rostock University Medical Center, 18057 Rostock, Germany., Woitas A; Department of Medicine II, Division of Gastroenterology and Endocrinology, Rostock University Medical Center, 18057 Rostock, Germany., Vorobyev A; Department of Dermatology, University of Lübeck, 23562 Lübeck, Germany., Ehlers L; Department of Medicine II, Division of Gastroenterology and Endocrinology, Rostock University Medical Center, 18057 Rostock, Germany., Ludwig RJ; Lübeck Institute of Experimental Dermatology and Center for Research on Inflammation of the Skin, University of Lübeck, 23562 Lübeck, Germany.; Department of Dermatology, University of Lübeck, 23562 Lübeck, Germany., Bieber K; Lübeck Institute of Experimental Dermatology and Center for Research on Inflammation of the Skin, University of Lübeck, 23562 Lübeck, Germany., Jaster R; Department of Medicine II, Division of Gastroenterology and Endocrinology, Rostock University Medical Center, 18057 Rostock, Germany. |
| Abstrakt: |
(1) Background: Autoimmune pancreatitis (AIP) is mainly treated with steroids. Using an AIP mouse model, we investigated two potential alternatives, the transforming growth factor-β-activated kinase 1 inhibitor, takinib, and the Janus kinase inhibitor, tofacitinib. (2) Methods: In a multicenter preclinical study, MRL/MpJ mice were injected with polyinosinic/polycytidylic acid (poly I:C) for two weeks to induce AIP. They were then treated for four weeks with either takinib (25, 50, or 75 mg/kg body weight), tofacitinib (5, 10 or 15 mg/kg), dexamethasone (1 mg/kg), or solvent, while the poly I:C injections were continued. The severity of AIP was assessed histopathologically. Flow cytometry was used to examine lymphocyte subtypes in the spleen and mesenteric lymph nodes. The pancreatic gene expression profiles were analyzed by RNA sequencing. (3) Results: Poly I:C-treated mice developed severe AIP with inflammation, destruction of acinar tissue, and fibrosis. Dexamethasone significantly attenuated the disease, while takinib or tofacitinib had no effects. Dexamethasone also antagonized the effects of poly I:C on the relative frequencies of the AIP-associated lymphocyte subtypes CD4/CD69, CD8/CD44 high , and CD4/CD25/FoxP3 in the spleen. In the principal component analysis of pancreatic transcriptomics, poly I:C-injected mice treated with tofacitinib, takinib, or solvent clustered together, while untreated and dexamethasone-treated mice formed separate, unique clusters. (4) Conclusions: Dexamethasone effectively reduced AIP severity, while takinib and tofacitinib were ineffective. The unique gene expression profile in dexamethasone-treated mice may provide a basis for identifying new drug targets for AIP treatment. |
